BACKGROUND: Pancreatic adenocarcinoma (PCa) is a disease with dismal prognosis, and the only possibility of cure, albeit small, is based on the combination of c
BACKGROUND:Rapamycin is a potent new immuno-suppressant with a mechanism of action that is distinct from that of calcineurin inhibitors, but few clinical data o